Skip to content

Similar metrics at other companies

Celldex Therapeutics logo
CLDXGrant — Revenue
$15K-97.7%
CRISPR Therapeutics logo
CRSPGrant — Revenue
$458K-47.1%
Vir Biotechnology, Inc. logo
VIRGrant revenue — Total revenues
$12K-99.0%
Kopin logo
KOPNGrant — Revenue
$3.44M+1,505%
Moderna logo
MRNAGrant revenue — Total Revenue
$0-100%
Kopin logo
KOPNGrant Income — Revenue
$3.44M+1,504%

Other financials

Income statement

See full
Revenue$37.2M-57.1%
Gross profit$63.0M-22.5%
Operating income-$68.9M-158%
Net income-$53.2M-182%
EPS (diluted)-$0.44-159%

Balance sheet

See full
Cash & equivalents$91.4M-16.9%
Total debt$39.4M+24.8%
Total equity$244.6M+0.7%
Total assets$520.0M+11.3%

Cash flow

See full
Operating cash flow$21.1M+206%
CapEx$3.1M-13.2%
Free cash flow$18.0M+176%

Valuation

See full
Market cap$312.68M-23.7%
Enterprise value$260.72M-21.3%
P/E115×
P/S0.6×-0.3×

Profitability

See full
Gross margin75.9%+0.8pp
Operating margin0.5%
Net margin0.5%+0.3pp
FCF margin6.9%

Returns & leverage

See full
Return on equity1.1%+0.6pp
Debt / equity0.2×0.0×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Organogenesis Holdings Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organogenesis Holdings Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organogenesis Holdings Inc.'s grant — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organogenesis Holdings Inc.'s grant — revenue?
Organogenesis Holdings Inc. (ORGO) reported grant — revenue of $978K in Q1 2026.
What does grant — revenue mean?
This metric represents the total revenue recognized from government or private research grants specifically allocated to the company's regenerative medicine development programs. It reflects the company's ability to secure non-dilutive funding to support innovation and clinical research activities within its specialized product segments. Tracking this revenue helps investors assess the external validation of the company's R&D pipeline and its success in leveraging external capital for product development.